Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.
Several other research firms have also commented on IMUX. Ladenburg Thalmann & Co. Inc. raised Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald started coverage on Immunic in a report on Friday, October 23rd. They issued an “overweight” rating for the company. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Immunic in a research note on Thursday, September 10th. Finally, Zacks Research cut shares of Immunic from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.43.
Check Out Our Latest Report on Immunic
Immunic Stock Performance
Shares of IMUX opened at $7.52 on Friday. The stock’s 50-day moving average is $8.70 and its two-hundred day moving average is $11.52. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43.
Immunic (NASDAQ:IMUX – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). As a group, equities analysts forecast that Immunic will post -3.69 EPS for the current year.
Institutional Trading of Immunic
A number of hedge funds and other institutional investors have recently modified their holdings of the business. CTC Alternative Strategies Ltd. purchased a new stake in shares of Immunic during the first quarter worth about $27,000. ADAR1 Capital Management LLC purchased a new position in Immunic in the first quarter valued at about $33,000. China Universal Asset Management Co. Ltd. boosted its holdings in Immunic by 21.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock valued at $69,000 after purchasing an additional 1,400 shares during the last quarter. Bank of America Corp DE boosted its holdings in Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares during the last quarter. Finally, Alps Advisors Inc. grew its stake in Immunic by 28.0% during the 3rd quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after purchasing an additional 3,870 shares in the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.
Key Immunic News
These are some of the IMUX news items that stood out recently:
- Neutral Sentiment: Immunic is preparing to start its Phase 3 PROTECT-MS trial for progressive MS, with first-patient enrollment expected in the first half of 2027. The company also announced leadership appointments intended to support regulatory and commercial readiness. Article: Immunic reports third-quarter 2026 financial results and provides corporate update
- Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
- Negative Sentiment: Zacks Research downgraded Immunic from “strong-buy” to “hold,” adding to near-term caution ahead of the trial results. Article: Zacks Research stock recommendations
About Immunic
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.
Read More
- Five stocks we like better than Immunic
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
